Behandling af neuroendokrine gastrointestinale tumorer

Carsten Palnaes Hansen; Seppo Langer; Susanne Frevert; Jann Mortensen; Andreas Kjær; Ulrich Knigge

Behandling af neuroendokrine gastrointestinale tumorer

Translated title of the contribution: [Treatment of neuroendocrine tumours of the gastrointestinal tract]

Carsten Palnaes Hansen, Seppo Langer, Susanne Frevert, Jann Mortensen, Andreas Kjær, Ulrich Knigge

Abstract

The prognosis of neuroendocrine tumours of the gastrointestinal tract and pancreas is difficult to estimate due to their heterogeneous nature. Survival without dissemination may reach 90%, while metastases reduce the 5-year survival to less than 50%. Radical surgery offers the only possibility of cure. Palliative therapy includes surgery and intra-arterial embolization of hepatic metastases, chemotherapy, biotherapy with interferon-alpha and radionuclear treatment. Tumour-targeted therapy with tyrosine kinase inhibitors, mammalian target of rapamycin inhibitors or monoclonal antibodies are under investigation in phase-III studies.

Translated title of the contribution	[Treatment of neuroendocrine tumours of the gastrointestinal tract]
Original language	Danish
Journal	Ugeskrift for Laeger
Volume	172
Issue number	43
Pages (from-to)	2942-5
Number of pages	4
ISSN	0041-5782
Publication status	Published - 25 Oct 2010

Cite this

@article{3adf6bb3158546539e79b5438c0f882f,

title = "Behandling af neuroendokrine gastrointestinale tumorer",

abstract = "The prognosis of neuroendocrine tumours of the gastrointestinal tract and pancreas is difficult to estimate due to their heterogeneous nature. Survival without dissemination may reach 90%, while metastases reduce the 5-year survival to less than 50%. Radical surgery offers the only possibility of cure. Palliative therapy includes surgery and intra-arterial embolization of hepatic metastases, chemotherapy, biotherapy with interferon-alpha and radionuclear treatment. Tumour-targeted therapy with tyrosine kinase inhibitors, mammalian target of rapamycin inhibitors or monoclonal antibodies are under investigation in phase-III studies.",

author = "Hansen, {Carsten Palnaes} and Seppo Langer and Susanne Frevert and Jann Mortensen and Andreas Kj{\ae}r and Ulrich Knigge",

year = "2010",

month = oct,

day = "25",

language = "Dansk",

volume = "172",

pages = "2942--5",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "43",

}

TY - JOUR

T1 - Behandling af neuroendokrine gastrointestinale tumorer

AU - Hansen, Carsten Palnaes

AU - Langer, Seppo

AU - Frevert, Susanne

AU - Mortensen, Jann

AU - Kjær, Andreas

AU - Knigge, Ulrich

PY - 2010/10/25

Y1 - 2010/10/25

N2 - The prognosis of neuroendocrine tumours of the gastrointestinal tract and pancreas is difficult to estimate due to their heterogeneous nature. Survival without dissemination may reach 90%, while metastases reduce the 5-year survival to less than 50%. Radical surgery offers the only possibility of cure. Palliative therapy includes surgery and intra-arterial embolization of hepatic metastases, chemotherapy, biotherapy with interferon-alpha and radionuclear treatment. Tumour-targeted therapy with tyrosine kinase inhibitors, mammalian target of rapamycin inhibitors or monoclonal antibodies are under investigation in phase-III studies.

AB - The prognosis of neuroendocrine tumours of the gastrointestinal tract and pancreas is difficult to estimate due to their heterogeneous nature. Survival without dissemination may reach 90%, while metastases reduce the 5-year survival to less than 50%. Radical surgery offers the only possibility of cure. Palliative therapy includes surgery and intra-arterial embolization of hepatic metastases, chemotherapy, biotherapy with interferon-alpha and radionuclear treatment. Tumour-targeted therapy with tyrosine kinase inhibitors, mammalian target of rapamycin inhibitors or monoclonal antibodies are under investigation in phase-III studies.

M3 - Tidsskriftartikel

SN - 0041-5782

VL - 172

SP - 2942

EP - 2945

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 43

ER -

Behandling af neuroendokrine gastrointestinale tumorer

Abstract

Fingerprint

Cite this